We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Diffusion Abnormality Index Provides Potential Imaging Biomarker to Indicate Brain Tumor Response to Radiation Therapy

By HospiMedica International staff writers
Posted on 18 Feb 2013
A new tool called the diffusion abnormality index (DAI) shows potential as an imaging biomarker to gauge brain tumor response to radiation therapy.

The study’s findings were presented February 9, 2013, at the 2013 Cancer Imaging and Radiation Therapy Symposium, held in Orlando (FL, USA). More...
This Symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North American (RSNA).

The study included 20 patients who had brain metastases and who were treated with whole brain radiotherapy. The 45 lesions among the patients were further categorized as 16 responsive, 18 stable, and 11 progressive. Diffusion measurements were taken prior to radiation treatment, two weeks after the start of treatment and one month after treatment completion. For each patient, a normal tissue apparent diffusion coefficient (ADC) histogram was used to divide the tumor ADC histogram into three regions: low (high cellularity), normal, and high (edema and necrosis) diffusion. Analyzing the complex behavior in ADC of brain metastases from preradiation therapy to two weeks after starting treatment, investigators developed a new diffusion index, the DAI, which included both low and high ADC contributions, for prediction of post-treatment tumor response.

Sensitivity and specificity of the change in DAI from pre- to the end of therapy were evaluated and compared with the changes in gross tumor volume from pretreatment to the end of therapy. The changes were helpful in predicting nonresponsive lesions post-treatment. Early prediction of brain tumor response to radiation therapy is vital in providing the most appropriate radiation doses to each lesion.

“While this review included a small number of patients, the data demonstrate that DAI may be a good biomarker to predict brain tumor response,” said lead study author Reza Farjam, a PhD candidate in biomedical engineering focused on cancer functional imaging at the University of Michigan (Ann Arbor, MI, USA). “Further study of this method is needed to improve early prediction of tumor response to radiation therapy and to help us provide brain cancer patients with more accurate information about their treatment progress.”

Related Links:

University of Michigan




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.